Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Mileshkin

Showing results (161-170 of 174) with videos related to

Pageof 18
Sort By:
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Nature Genetics|February 28, 2023
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancerNikki L Burdett, Madelynne O Willis, Kathryn Alsop, et al.
Lancet (London, England)|April 13, 2026
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trialDomenica Lorusso, Laurence Gladieff, David M O'Malley, et al.
Histopathology|March 31, 2023
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programmeHeather Thorne, Lisa Devereux, Jason Li, et al.
Nature Communications|May 20, 2025
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primaryRichard J Rebello, Atara Posner, Ruining Dong, et al.
Lancet (London, England)|June 5, 2025
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trialAlexander B Olawaiye, Laurence Gladieff, David M O'Malley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2017
Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian CancerDale W Garsed, Kathryn Alsop, Sian Fereday, et al.
American Journal of Human Genetics|March 3, 2023
Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcareZornitza Stark, Tiffany Boughtwood, Matilda Haas, et al.
Pageof 18

Showing results (161-170 of 174) with videos related to

Sort By:
Pageof 18
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Nature Genetics|February 28, 2023
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancerNikki L Burdett, Madelynne O Willis, Kathryn Alsop, et al.
Lancet (London, England)|April 13, 2026
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trialDomenica Lorusso, Laurence Gladieff, David M O'Malley, et al.
Histopathology|March 31, 2023
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programmeHeather Thorne, Lisa Devereux, Jason Li, et al.
Nature Communications|May 20, 2025
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primaryRichard J Rebello, Atara Posner, Ruining Dong, et al.
Lancet (London, England)|June 5, 2025
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trialAlexander B Olawaiye, Laurence Gladieff, David M O'Malley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2017
Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian CancerDale W Garsed, Kathryn Alsop, Sian Fereday, et al.
American Journal of Human Genetics|March 3, 2023
Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcareZornitza Stark, Tiffany Boughtwood, Matilda Haas, et al.
Pageof 18